We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 0.67% | 1,647.00 | 1,646.50 | 1,647.00 | 1,656.00 | 1,635.00 | 1,642.00 | 1,900,747 | 14:00:40 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.78 | 67.89B |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said Tuesday that a clinical trial of its cancer drug dostarlimab yielded positive preliminary results.
The ongoing study, called Garnet, is examining the effects of dostarlimab on women with advanced or recurrent endometrial cancer who had their disease progress after chemotherapy. Dostarlimab is an asset that Glaxo acquired when it bought oncology specialist Tesaro Inc. in December 2018.
Data shows that dostarlimab administration of is having an effect on the disease, Glaxo said. The British pharmaceutical company said that disease control rate--a measure of efficacy of treatment--totaled 53% for patients administered the drug.
The study revealed that so far, 88 out of 125 patients had at least one adverse even in the course of treatment, but these were for the most part low-grade. Glaxo said that 13.6% of patients experienced grade 3 or higher events, and no deaths occurred due to treatment.
The FTSE 100-listed drugmaker said it plans to submit a license application for the drug as a treatment for endometrial cancer at the end of 2019.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
March 19, 2019 14:28 ET (18:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
